Metabolic medicines
Dulaglutide
A GLP-1 receptor agonist with long-term cardiovascular evidence in type 2 diabetes and an exploratory kidney-outcome analysis.
Large randomized human cardiovascular trial; exploratory renal analysis
Also known as: Trulicity
Practical use
Applying the explained evidence
- Where it fits
- A GLP-1 receptor agonist with long-term cardiovascular evidence in type 2 diabetes and an exploratory kidney-outcome analysis.
- Put the information into practice
- The useful questions are whether clinical events changed, which kidney components drove the result and whether the patient resembles the studied population.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- The renal-replacement component was imprecise and not independently significant.
Overview
Dulaglutide enhances glucose-dependent insulin release and reduces glucagon signaling while slowing gastric emptying. US approvals concern type 2 diabetes and cardiovascular risk reduction in eligible adults; a diabetes medicine is not automatically an approved obesity treatment.
Risks and limitations
GI effects are common. Pancreatitis, gallbladder disease, severe allergy and dehydration-related kidney injury are important warnings. Insulin or sulfonylureas increase hypoglycemia risk. Thyroid C-cell tumors occurred in rodents; human relevance is unknown, and MTC/MEN2 histories are contraindications.
How to read this
The useful questions are whether clinical events changed, which kidney components drove the result and whether the patient resembles the studied population.
Research explained
REWIND: cardiovascular outcomes
Who was studied
9,901 people aged at least 50 with type 2 diabetes and previous cardiovascular disease or risk factors; 24 countries, median follow-up 5.4 years.
- Dulaglutide: cardiovascular event
- 12 percent
- Placebo: cardiovascular event
- 13.4 percent
What was found
The primary cardiovascular composite occurred in 12.0% with dulaglutide and 13.4% with placebo (HR 0.88; 95% CI 0.79 to 0.99). GI adverse events were reported by 47.4% versus 34.1%.
What it cannot establish
All-cause mortality was not significantly different (HR 0.90; 95% CI 0.80 to 1.01). A positive composite does not mean every individual outcome improved.
Read the original studyREWIND: exploratory renal outcome
Who was studied
The same 9,901 participants, not an independent second trial; mean baseline eGFR 76.9 mL/min/1.73 m².
- Dulaglutide: renal composite
- 17.1 percent
- Placebo: renal composite
- 19.6 percent
What was found
New macroalbuminuria, sustained eGFR decline of at least 30%, or chronic renal replacement therapy occurred in 17.1% versus 19.6% (HR 0.85; 95% CI 0.77 to 0.93).
What it cannot establish
The clearest component was new macroalbuminuria (HR 0.77). eGFR decline and renal replacement components separately had confidence intervals crossing 1. This does not prove prevention of dialysis.
Read the original studyAbsolute and relative benefit
The primary cardiovascular event proportions differed by 1.4 percentage points over 5.4 years. A 12% relative hazard reduction is not a 12-percentage-point absolute change.
Supporting sourceKidney endpoints have different importance
Urinary albumin, loss of filtration and dialysis are distinct outcomes. A composite driven mainly by albuminuria should not be advertised as an equivalent reduction in kidney failure.
Supporting sourceEye disease needs its own context
The label reports retinopathy complications in 1.9% versus 1.5% overall. Existing retinopathy warrants monitoring; rapid glucose improvement can temporarily worsen retinal disease.
Supporting sourceDigestion matters beyond nausea
Severe gastroparesis is a reason the label does not recommend treatment. Delayed stomach emptying also matters for oral medicines and anesthesia; disclose treatment before procedures.
Supporting sourceEvidence does not establish enhancement protection
These trials do not test whether dulaglutide offsets cardiovascular or kidney injury caused by performance drugs.
Supporting sourceClaims versus findings
Overstated
A lower renal composite proves that dialysis was prevented.
The renal-replacement component was imprecise and not independently significant.
Check the evidenceCommon questions
Is the kidney analysis a second independent trial?
No. It examines additional outcomes in the same REWIND participants.
SourceSources
REWIND: cardiovascular outcomes
REWIND: exploratory renal outcome
Sources checked 2026-09-29.
General education; not a personal treatment plan.